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Abstract In the brain, approximately 90% of oxylipins
are esteriﬁed to lipids. However, the signiﬁcance of this
esteriﬁcation process is not known. In the present study, we
(1) validated an aminopropyl solid phase extraction (SPE)
method for separating esteriﬁed lipids using 100 and
500 mg columns and (2) applied the method to quantify the
distribution of esteriﬁed oxylipins within phospholipids
(PL) and neutral lipids (NL) (i.e. triacylglycerol and
cholesteryl ester) in rats subjected to head-focused
microwave ﬁxation (controls) or CO2-induced hypercapnia/
ischemia. We hypothesized that oxylipin esteriﬁcation into
these lipid pools will be altered following CO2-induced
hypercapnia/ischemia. Lipids were extracted from control
(n = 8) and CO2-asphyxiated (n = 8) rat brains and sepa-
rated on aminopropyl cartridges to yield PL and NL. The
separated lipid fractions were hydrolyzed, puriﬁed with
hydrophobic–lipophilic–balanced SPE columns, and ana-
lyzed with ultra-high-pressure liquid chromatography
coupled to tandem mass spectrometry. Method validation
showed that the 500 mg (vs 100 mg) aminopropyl columns
yielded acceptable separation and recovery of esteriﬁed
fatty acid epoxides but not other oxylipins. Two epoxides
of arachidonic acid (ARA) were signiﬁcantly increased,
and three epoxides of docosahexaenoic acid (DHA) were
signiﬁcantly decreased in brain NL of CO2-asphyxiated rats
compared to controls subjected to head-focused microwave
ﬁxation. PL-bound fatty acid epoxides were highly variable
and did not differ signiﬁcantly between the groups. This
study demonstrates that hypercapnia/ischemia alters the
concentration of ARA and DHA epoxides within NL,
reﬂecting an active turnover process regulating brain fatty
acid epoxide concentrations.
Keywords Arachidonic acid and docosahexaenoic acid
epoxides  Eicosanoids  Esteriﬁed oxylipins  Hypercapnia/
ischemia  Rat brain  Turnover
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CE cholesteryl ester
COX cyclooxygenase
CYP cytochrome p450
DAG diacylglycerols
DHA docosahexaenoic acid
DiHETE dihydroxyeicosatetraenoic acid
DiHETrE dihydroxyeicosatrienoic acid
DiHOME dihydroxyoctadecenoic acid
DPPC 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine
EDTA Ethylenediaminetetraacetic acid
EPA eicosapentaenoic acid
EpDPE epoxydocosapentaenoic acid
EpETE epoxyeicosatetraenoic acid
EpETrE epoxyeicosatrienoic acid
EpOME epoxyoctadeenoic acid
FFA unesteriﬁed fatty acids
GC gas chromatography
HDoHE hydroxydocosahexaenoic acid
HEPE hydroxyeicosapentaenoic acid
HETE hydroxyeicosatetraenoic acid
HETrE hydroxyeicosatrienoic acid
HODE hydroxyoctadecadienoic acid
HOTrE hydroxyoctadecatrienoic acid
LNA linoleic acid
LOQ limits of quantitation
LOX lipoxygenase
LT leukotriene
LysoPL lysophospholipids
NL neutral lipids
oxo-ETE oxo-eicosatetraenoic acid
oxo-ODE oxo-octadecadienoic acid
PG prostaglandin
15-PGDH 15-hydroxyprostaglandin dehydrogenase
PL phospholipids
PUFA polyunsaturated fatty acids
sEH soluble epoxide hydrolase
SPE solid phase extraction
TAG triacylglycerols
TPP triphenylphosphine
TXB2 tromboxane B2
UPLC–
MS/MS
ultra-high-pressure liquid chromatography
tandem mass spectrometry
TriHOME trihydroxyoctadecenoic acid.
Introduction
Polyunsaturated fatty acids (PUFA) are precursors to hun-
dreds of bioactive lipid mediators known as oxylipins.
PUFA can be converted into oxylipins via auto-oxidation
or a host of enzymes, including cyclooxygenase (COX)
(Funk, 2001; Laneuville et al., 1995), lipoxygenase (LOX)
(Chang et al., 2015; Murphy et al., 1995), cytochrome p450
(CYP) (Arnold et al., 2010; Fer et al., 2008a, b),
15-hydroxyprostaglandin dehydrogenase (15-PGDH)
(Snyder et al., 2015; Wendell et al., 2015), and soluble
epoxide hydrolase (sEH) enzymes (Greene et al., 2000;
Inceoglu et al., 2007).
In peripheral tissue and brain, oxylipins regulate multi-
ple biological processes, including angiogenesis (Rand
et al., 2017), vasodilation (Inceoglu et al., 2012; Liu et al.,
2011), vasoconstriction (Dabertrand et al., 2013), signal-
ing (Hennebelle et al., 2017), inﬂammation (Rey et al.,
2016), and the resolution of inﬂammation (Levy et al.,
2001; Orr et al., 2013; Serhan et al., 2002). In particular,
CYP-derived epoxides of n-6 arachidonic acid (ARA,
20:4n-6) and n-3 eicosapentaenoic acid (EPA, 20:5n-3)
and docosahexaenoic acid (DHA, 22:6n-3) have been
reported to suppress brain inﬂammation, promote resolu-
tion, and increase axonal outgrowth (Abdu et al., 2011;
Vito et al., 2014).
In the brain (and other tissues), the majority of PUFA,
such as ARA and DHA, are esteriﬁed to membrane phos-
pholipids (PL), where they undergo rapid turnover (acyla-
tion/deacylation) (Rapoport, 1996; Robinson and Rapoport,
1989) via the “Lands Pathway” (Lands and Merkl, 1963).
Neuroreceptor-coupled phospholipase A2 activation or
brain injury (e.g. ischemia) induces the release of bound
PUFA (Bazan Jr., 1970; Ramadan et al., 2011; Taha et al.,
2014), resulting in an increase in unesteriﬁed fatty acids
(FFA) (Bazan Jr., 1970) and their COX-, LOX-, 15-PGDH-
, CYP-, or sEH-derived metabolites (Hennebelle et al.,
2017, 2019). PUFA-derived oxylipins exert their biological
effects when present in the unesteriﬁed (i.e. free) form
(Lahvic et al., 2018; Obinata et al., 2005). In the brain,
however, the majority of oxylipins (up to approximately
90%) are esteriﬁed, presumably to lipids (Taha et al.,
2018). The type of lipids they are esteriﬁed to and how this
process is regulated in the brain are not known.
Previous studies have shown that oxylipins esteriﬁed to PL or
neutral lipids (NL) composed mainly of triacylgycerols (TAG) and
cholesteryl esters (CE), can be liberated via lipase enzymes
(Chaitidis et al., 1998; Morrow et al., 1992; Wang et al., 2009) fol-
lowing the induction of inﬂammatory pathways by FFA addition
to cell culture or carbon tetrachloride injection to rats (Morrow
et al., 1992; Wang et al., 2009). The formation of esteriﬁed
oxylipins was reported to occur via direct auto- or LOX-mediated
oxidation of PUFA esteriﬁed to PL (Chaitidis et al., 1998; Morrow
et al., 1992). Recently, however, Klett et al. reported that, in vitro,
unesteriﬁed ARA-derived hydroxyeicosatetraenoic acids (HETE)
and epoxyeicosatrienoic acids (EpETrE) can be esteriﬁed to
lysophospholipids following their acylation by acyl-CoA synthe-
tase (Klett et al., 2017). This is consistent with studies showing that
labeled HETE incorporate into NL or PL of human polymorpho-
nuclear leukocytes and isolated neutrophils and platelets (Brezinski
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and Serhan, 1990; Joulain et al., 1995; Stenson and Parker,
1979a), and EpETrE incorporate into the PL of mastocytoma cells
(Bernstrom et al., 1992) and isolated porcine coronary artery and
endothelial cells (Fang et al., 2003).
A recent study by Liu et al. showed an alternative pathway
for oxidized PL formation, where LOX oxidizes
lysophospholipids containing ARA at the sn-2 position to form
15-HETE lysophospholipid, which is then esteriﬁed to a satu-
rated fatty acid via an sn-1 acyltransferase (Liu et al., 2019).
The formation of oxidized PL via this pathway was upregulated
following thrombin treatment of platelets (Liu et al., 2019).
Others reported direct and increased esteriﬁcation of HETE
and EpETrE into PL or NL following pharmacological stimu-
lation of polymorphonuclear leukocytes or isolated neutrophils
and platelets (Brezinski and Serhan, 1990; Stenson and Parker,
1979b). Collectively, these studies suggest that, in vivo,
oxylipins may incorporate into PL and NL pools via multiple
regulated pathways, consistent with evidence showing that the
majority of oxylipins in rat brain are esteriﬁed (Taha
et al., 2018).
In the present study, we ﬁrst conﬁrmed the validity of
an established aminopropyl column method used to isolate
oxylipins esteriﬁed to PL and NL (Grapov, 2012; Wang
et al., 2009), and then applied the method to test whether
esteriﬁed oxylipin pools are altered in rat brain following
CO2-induced hypercapnia/ischemia. We hypothesized
that, similar to well-established processes governing the
lipase-mediated release of esteriﬁed oxylipins during
inﬂammation (Morrow et al., 1992; Wang et al., 2009),
ischemia-induced brain injury would increase the esteriﬁ-
cation of free oxylipins into various lipid pools. This arti-
cle provides evidence in support of the hypothesis,
suggesting the existence of a turnover pathway guiding
the release and esteriﬁcation of unesteriﬁed oxylipins
in vivo.
Materials and Methods
Materials
Fatty acid standards were purchased from Nu-chek Prep
Inc. (Elysian, MN, USA). PL standards were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). Seventy-
two oxylipin standards, listed in Supplementary Table 1,
and their deuterated surrogate standards (nine in total)
were purchased from Cayman Chemical (Ann Arbor, MI,
USA) or Larodan (Monroe, MI, USA). All solvents
were LC–MS grade and were purchased from Fisher
Scientiﬁc (Santa Clara, CA, USA). Concentrated HCl
(ACS reagent, 37%) for fatty acid transesteriﬁcation reac-
tions was purchased from Sigma Aldrich (St. Louis,
MO, USA)
Ischemia Study
Animals
All procedures were performed in accordance with the poli-
cies of the Canadian Council on Animal Care and were
approved by the Animal Ethics Committee of the Univer-
sity of Toronto.
In the present study, we used the entire left hemisphere
(containing cerebrum, cerebellum, and brainstem) of rats
from a recently published study that compared the effects
of CO2-induced hypercapnia/ischemia and high-energy
microwave ﬁxation on free oxylipin concentrations
(Hennebelle et al., 2019). In brief, 1-month-old Long Evans
male rats were purchased from Charles River (Saint-Con-
stant, QC, Canada) and housed in pairs. The rats were fed
ad libitum for 30 days with a rat chow diet containing 6.2%
fat by weight (2018 Teklad Global, 18% protein rodent
diet; Envigo, Madison, WI, USA). The fatty acid composi-
tion of the diet (% of total fatty acids) was 18.5% palmitic
acid (16:0), 2.8% stearic acid (18:0), 18.5% oleic acid (18:1
n-9), 54.8% linoleic acid (LNA; 18:2 n-6), and 5.6%
α-linolenic acid (ALA; 18:3 n-3) (Trepanier et al., 2012).
Experiments were performed after the animals were
housed at our facility for approximately one month (i.e. day
60 onward) to (1) minimize the potential effects of hor-
monal changes associated with puberty occurring at
~42 days of age in this strain of rats (Ge et al., 2007) and
(2) to acclimatize the animals to the Teklad Global diet pro-
vided in the facility, which differs in fatty acid composition
from the diet at Charles River. The Charles River diet con-
tains ﬁsh meal, whereas the Teklad Global diet is based on
plant oils.
Rats (n = 8) were subjected to head-focused microwave
ﬁxation (13.5 kW for 1.6 s, Cober Electronics Inc., Nor-
walk, CT, USA) to halt brain lipid metabolism or CO2
asphyxiation for 2 min (n = 8) to induce global brain
hypercapnia/ischemia. The heads were decapitated, and the
brains were excised within 6.5 min, ﬂash frozen in liquid
nitrogen, and stored in a −80C freezer. Samples were
shipped on dry ice from Toronto, ON, Canada to Davis,
CA, USA, where they were maintained in a −80 C freezer
until they were analyzed.
Validation of the NL and PL Separation Method
The PL and NL separation method was validated using an
aminopropyl column (particle size 40 μm; Agilent Bond
Elut NH2, Agilent Corporation, Palo Alto, CA, USA) as
previously described (Grapov, 2012; Wang et al., 2009).
The separation of PL, CE, TAG, and FFA lipid standards
and free oxylipin standards was tested using two sizes of
aminopropyl columns—100 and 500 mg. The accuracy of
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the method was also assessed on one rat brain hemisphere
using both columns.
Separation of PL, CE, TAG, and FFA Standards with
Aminopropyl Columns
The elution of free and esteriﬁed lipid standards was tested
using the 100 and 500 mg solid phase extraction (SPE) col-
umns. Our goal was to determine the optimal column ﬁlter
material and solvent volumes that would separate the lipid
fractions (smaller columns require less solvent). The sol-
vent elution sequence and volumes used for each column
size are presented in Table 1. As shown, the columns were
ﬁrst preconditioned by gravity elution with methanol,
water, 0.1 M HCl, and hexane. The 100 and 500 mg
aminopropyl columns were then loaded with 0.2 and 1 mg,
respectively, of each of the following lipid standards dis-
solved in 100 μL chloroform: unesteriﬁed palmitic acid,
cholesteryl palmitate, tripalmitin, or 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC). Hence, each standard
was applied separately to each of the 100 and 500 mg col-
umns (i.e. four standards at 0.2 mg each, applied separately
to the 100 mgs column and four standards at 1 mg each,
applied separately to the 500 mgs column—total of eight
columns). Standard purity was conﬁrmed by gas chroma-
tography (GC) coupled to ﬂame-ionization detection prior
to loading them on the columns. NL containing tripalmitin
and cholesteryl palmitate were eluted with hexane and hex-
ane:chloroform:isopropanol (100:5:5). FFA were eluted
with chloroform:isopropanol (2:1, v/v). PL were eluted
with 10% acetic acid in methanol (v/v) after washing the
columns with diethyl ether containing 2% acetic acid.
The lipid fractions (PL, NL, and FFA) were collected
from each column, dried under nitrogen, and reconstituted
in 400 μL toluene. Unesteriﬁed heptadecanoic acid was
added to the collected unesteriﬁed fraction;
triheptadecanoin was added to the collected cholesteryl pal-
mitate and tripalmitin fractions (which elute in the NL frac-
tion); and diheptanoyl phosphatidylcholine was added to
the collected DPPC fraction. The amount of heptadecanoic
acid standard added to each of the free palmitate-,
tripalmitin-, and DPPC fractions eluted by the 100 and
500 mg aminopropyl columns was 0.04 and 0.2 mg,
respectively. The amount of triheptadecanoin added to
cholesteryl palmitate fractions was 0.02 and 0.1 mg for the
100 and 500 mg columns, respectively.
The eluted lipids in each fraction were transesteriﬁed by
adding 3 mL methanol and 600 μL of 8% concentrated HCl
in methanol and heating them at 90 C for 1 h. After
cooling, 1 mL of hexane and 1 mL of water were added.
The samples were vortexed and allowed to sit undisturbed
for 10 min to enable separation of the hexane and aqueous
phases. A total of 900 μL of the upper hexane layer con-
taining the fatty acid methyl esters were transferred to a
new tube containing 450 μL water. Samples were vortexed
and centrifuged for 2 min at 15,871 ×g. The upper hexane
layer was dried under nitrogen, reconstituted in 100 μL
hexane, and transferred to amber GC vials containing
inserts.
Fatty acids methyl esters were analyzed on a Perkin
Elmer Clarus 500 GC system (Perkin Elmer, Richmond,
CA, USA) equipped with a FFAP-fused silica capillary col-
umn (Length: 30 m, Inner Diameter: 0.25 mm, Film thick-
ness: 0.25 μm; Agilent Technologies, Santa Clara, CA,
USA). The injector temperature was set at 240 C and the
detector at 300 C. Helium was used as a carrier gas at a
constant ﬂow rate of 1.3 mL/min. The oven temperature
was set at 80 C for 2 min, increased to 185 C by 10 C/
Table 1 Solid phase extraction (SPE) protocol used to separate NL, FFA, and PL on 100 and 500 mg aminopropyl columns
Extraction steps Solvents/Samples Volume of solvents
100 mg columns 500 mg columns
Conditioning Methanol 2 mL 6 mL
Water 2 mL 6 mL
0.1 M aq. HCl 2 mL 6 mL
Water 4 mL 12 mL
Methanol 2 mL 6 mL
Hexane 6 mL 18 mL
Loading samples Lipids 0.2 mg 1 mg
NL elution Hexane 2.5 mL 7.5 mL
Hexane:chloroform:ethylacetate (100:5:5, v:v:) 2 mL 6 mL
FFA elution Chloroform:Isopropanol (2:1, v:v) 2 mL 6 mL
Wash Acetic acid:diethyl ether (2:98, v:v) 2 mL 6 mL
PL elution Acetic acid:methanol (10:90, v:v) 5 mL 15 mL
FFA, unesteriﬁed fatty acids; NL, neutral lipids; PL, phospholipids.
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min and to 240 C by 5 C/min, and maintained at 240 C
for 13 min. Fatty acids were identiﬁed based on the reten-
tion times of a custom mix of 29 fatty acid methyl ester
standards.
Fatty acid and internal standard (heptadecanoic acid)
peak areas were used to determine the amount (nmol) of
free or esteriﬁed palmitic acid standard collected in each
lipid pool (FFA, PL, and NL). They were added to deter-
mine the total amount of fatty acids per fraction and the
sum was divided by the actual amount we added to the col-
umn to determine percent recovery, as follows:
Percent recovery %ð Þ
=
P
Amount nmolð Þ in each eluted fraction
Amount nmolð Þadded to the column × 100
Determination of Free Oxylipin Elution Proﬁle on the
Aminopropyl Columns
A mixture of 72 free oxylipin standards (listed in Supple-
mentary Table 1), ranging in amount between 2.5 and
62.5 pmol, was loaded onto both aminopropyl columns
(n = 1 per column) to conﬁrm that free oxylipins eluted
with the FFA fraction. The elution sequence described in
Table 1 was applied, and NL, FFA, and PL fractions were
collected. Each fraction was dried under nitrogen and rec-
onstituted in 200 μL methanol containing 0.1% acetic acid
and 0.1% butylated hydroxytoluene (BHT), 10 μL of antiox-
idant mix (0.2 mg/mL BHT, ethylenediaminetetraacetic acid
[EDTA] and triphenylphosphine [TPP] in methanol: water,
1:1, v:v) after being spiked with 10 μL surrogate standard
solution containing 2 μM of d11-11(12)-EpETrE,
d11-14,15-DiHETrE, d4-6-keto-PGF1α, d4-9-HODE,
d4-LTB4, d4-PGE2, d4-TXB2, d6-20-HETE, and
d8-5-HETE in methanol. d4-PGE2 was only used for quan-
tifying free oxylipins with similar retention times on the LC
column, speciﬁcally LNA-derived trihydroxylated metabo-
lites (9,10,13-TriHOME and 9,12,13-TriHOME),
prostanoids (15-deoxy-PGJ2, PGF2-alpha, PGB2, PGD2,
PGD3, PGE1, PGE2, PGE3 and PGJ2), and the hydroxyl-
ated EPA metabolite Resolvin E1. Retention times for each
compound are provided in Supplementary Table 1.
d4-PGE2 was not used to quantify esteriﬁed concentrations
of these metabolites because it degrades during the hydroly-
sis process.
Ultrapure water (1.8 mL) was added to the samples,
which were then loaded onto the 60 mg Oasis HLB col-
umns. All columns prerinsed with one volume of ethyl ace-
tate and two volumes of methanol and preconditioned with
two volumes of SPE buffer containing 5% methanol and
0.1% acetic acid in ultrapure Millipore water (Hennebelle
et al., 2017). The columns were rinsed twice with SPE
buffer before being subjected to 20 min of vacuum
(≈20 psi). Oxylipins were eluted with 0.5 mL methanol
and 1.5 mL ethyl acetate in 2 mL centrifuge tubes. Samples
were dried under nitrogen, reconstituted in 100 μL metha-
nol, and subjected to mass spectrometry analysis (ultra-
high-pressure liquid chromatography tandem mass spec-
trometry [UPLC–MS/MS]) as described below. Quantita-
tion was achieved using the surrogate standard after
correcting for the response factor using a calibration curve
for each oxylipin.
The percent recovery of each oxylipin within PL, NL, or
FFA separated by the aminopropyl columns was calculated
as follows:
Percent recovery %ð Þ
=
P
Amount nmolð Þdetected in each eluted fraction
Amount nmolð Þ added to the column × 100
Brain Extract Fractionation
The separation efﬁciency of esteriﬁed oxylipins with both
columns (100 and 500 mg) was tested on one rat brain
hemisphere and compared. Total lipids were extracted
using a modiﬁed Folch procedure (Trepanier et al., 2012).
Approximately 800 mg of a rat brain sample were homoge-
nized in 5 mL methanol containing 0.01% BHT. Five mL
of methanol and 20 mL of chloroform were then added to
reach a ﬁnal chloroform:methanol ratio of 2:1. The samples
were vortexed, and 7.5 mL of 0.1 M NaCl were added. The
samples were vortexed again and centrifuged at 730 ×g for
5 min. The bottom chloroform layer containing total lipids
was transferred to a new tube. The lipid extraction process
was repeated by adding 15 mL of chloroform, centrifuging,
and pooling the bottom chloroform layer with the ﬁrst one.
The chloroform extract was dried under nitrogen and rec-
onstituted in 8 mL chloroform (or approximately 10 mg of
fat/mL chloroform on the basis that the brain contains
~10% fat).
A total of 20 μL of total lipid extract containing ~0.2 mg
lipid was loaded onto the 100 mg column; 100 μL of total
lipid extract containing ~1 mg lipid was loaded onto the
500 mg column. NL, PL, and FFA were separated using
the solvent elution sequence and volumes detailed in
Table 1. All collected fractions were dried under nitrogen
and reconstituted in 200 μL methanol containing 0.1%
acetic acid and 0.1% BHT, 10 μL of antioxidant mix, and
10 μL surrogate standard solution. Esteriﬁed oxylipins from
PL and NL fractions were hydrolyzed in 200 μL of 0.25 M
sodium carbonate in methanol/water (1:1) at 60 C for
30 min. The samples were cooled at room temperature, and
25 μL of acetic acid and 1575 μL of Millipore water were
added prior to SPE (60 mg Oasis HLB columns). Free
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oxylipins collected in the FFA fraction were diluted with
1.8 mL ultrapure water and directly puriﬁed with 60 mg
Oasis HLB 3cc columns (Waters, Milford, MA, USA).
SPE columns were prerinsed with one volume of ethyl ace-
tate and two volumes of methanol and preconditioned with
two volumes of SPE buffer containing 5% methanol and
0.1% acetic acid in ultrapure Millipore water, as described
above. The columns were rinsed twice with SPE buffer and
subjected to 20 min of vacuum to dry (≈20 psi). Oxylipins
were eluted with 0.5 mL methanol and 1.5 mL ethyl ace-
tate, reconstituted in 100 μL methanol, ﬁltered by centrifu-
gation using Ultrafree-MC centrifugal ﬁlters (0.1 μm;
Millipore, Bedford, MA, USA), and subjected to UPLC–
MS/MS analysis (see below). Oxylipins were quantitated
using the surrogate standard (to correct for losses during
the extraction), after adjusting for the response factor of
each oxylipin using a calibration curve.
Esteriﬁed Oxylipin Analysis of Rat Brain Subjected to
Microwave Fixation or CO2-Induced Hypercapnia/
Ischemia
Because the 500 mg aminopropyl columns yielded bet-
ter results than the 100 mg columns (see Results), they
were used to separate total lipid extracts from the rat
brain samples subjected to high-energy microwave ﬁx-
ation or CO2-induced hypercapnia/ischemia (n = 8 per
group). Total lipids were ﬁrst extracted with chloro-
form/methanol (2:1 v/v) using a modiﬁed Folch proce-
dure utilizing lower solvent volumes (Folch et al.,
1957). Approximately 680–1028 μL of precooled 0.9%
KCl (w/v) solution containing 1 mM of EDTA was
added to an equal mass (680–1028 mg) of frozen brain
tissue (one hemisphere), yielding a 50% mixture (w/v).
The samples were homogenized with zirconia beads in
a Bullet Blender (Next Advance, Troy, NY, USA). A
total of 600 μL of the 50% homogenate mixture was
mixed with 600 μL of 0.9% KCl (w/v) aqueous solu-
tion containing 1 mM of EDTA, and 4.8 mL of chlo-
roform: methanol (2:1, v/v) containing 0.002% BHT.
The extract was centrifuged at 1000 ×g for 10 min at
4 C. The lower chloroform layer containing total
lipids was collected. The remaining aqueous layer con-
taining a semisolid interface was re-extracted with
chloroform:methanol (10:1, v/v). The mixture was
vortexed and centrifuged at 1000 ×g for 10 min at
4 C. The lower chloroform layer was combined with
the ﬁrst chloroform extract and dried under nitrogen
gas. The dried extract was redissolved in 3 mL of
chloroform.
PL and NL in 100 μL chloroform were separated using
the 500 mg aminopropyl SPE column and were hydrolyzed
and puriﬁed with the 60 mg Oasis HLB column as
described above (for the brain test sample).
UPLC–MS/MS Analysis
Oxylipins were analyzed within a week following extrac-
tion to minimize the potential impact of prolonged storage
on lipid oxidation. The samples were stored in a −80 C
freezer during this period. Seventy-two oxylipins were ana-
lyzed on an Agilent 1290 LC (Agilent Corporation)
coupled to an Agilent 6460 Triple Quadrupole MS (Agilent
Corporation). Oxylipin species were separated on an
Agilent Eclipse Plus C18 column (2.1 × 150 mm, 1.8 μm,
Agilent Corporation) with a binary gradient consisting of
solvent A (water containing 0.1% acetic acid) and solvent
B (Acetonitrile: methanol 80:15 containing 0.1% acetic
acid). The autosampler temperate was 4 C and the column
temperature was maintained at 45 C. The gradient proﬁle
is shown in Supplementary Table 2. Oxylipins were ionized
with negative-mode electrospray ionization. The ion source
gas temperature was 250 C, gas ﬂow was 10 L/min, sheath
gas temperature was 300 C, sheath gas ﬂow was 11 mL/
min, nebulizers were at 35 psi, and the capillary gas was at
3500 V/-3500 V. Optimization parameters and ion pairs for
each oxylipin are described in Supplementary Table 1.
Oxylipins were detected using dynamic multiple reaction
monitoring mode.
Statistical Analysis
All data are expressed as mean  SD. Differences between
the 100 and 500 mg columns were assessed using an
unpaired t-test (GraphPad Prism 7.04, La Jolla, CA, USA).
Differences between the head-focused microwave ﬁxation
and CO2 hypercapnia/ischemia groups were assessed on
GraphPad Prism with an unpaired t-test or Mann–Whitney
U test depending on whether the data were normally dis-
tributed or not based on Shapiro–Wilk’s test. Oxylipins
with more than 70% values above the limits of quantitation
(LOQ) ina given group were analyzed. For these oxylipins,
missing values were imputed by dividing the LOD by the
square root of 2. Statistical signiﬁcance was set at p < 0.05.
Results
Lipid Class Separation
The purity of the unesteriﬁed palmitic acid, cholesteryl pal-
mitate, tripalmitin, and DPPC were veriﬁed by GC. All
standards were over 98% pure (Supplementary Table 3).
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The remaining <2% impurities consisted of palmitoleic
acid and an unknown peak at 10.5 min in all fractions.
Table 2 shows the percent recovery of unesteriﬁed and
esteriﬁed palmitate following separation with the 100 and
500 mg aminopropyl columns. As shown, 93% and 92% of
unesteriﬁed palmitate were retained in the FFA fraction col-
lected from the 100 and 500 mg columns, respectively. The
NL fraction collected from the 100 and 500 mg columns
contained 82% and 105% of the added cholesteryl palmi-
tate, respectively. It also contained 109% (100 mg column)
and 101% (500 mg column) of the added tripalmitin
(i.e. TAG). The PL fraction retained 102% of the added
DPPC on the 100 mg column and 92% on the 500 mg col-
umn. Thus, both columns separated free and esteriﬁed fatty
acid standards, but the 500 mg column yielded greater
recovery of esteriﬁed lipids (92–105%) compared to the
100 mg column (82–109%).
GC analysis also showed the presence of other fatty
acids in the separated FFA, NL, and PL, which appear to
have originated from the columns (Supplementary
Table 4). However, none of the detected fatty acids (stearic
(18:0), oleic (18:1 n-9), linoleic (18:2 n-6), and α-linolenic
(18:3 n-3) acid) served as precursors to long-chain PUFA
oxylipins of interest or those that were well separated by
the columns (see next section).
Partition of Free Oxylipin Standards
Table 3 shows the percent recovery of 72 unesteriﬁed
oxylipin standards, applied directly to each of the 100 and
500 mg aminopropyl columns, within FFA, NL, and PL.
Our goal here was to ensure that free oxylipins eluted in
the FFA fraction.
Total % recovery of free epoxy, hydroxy, and ketone
PUFA metabolites, reﬂecting the total amount obtained in
each fraction relative to the amount applied to the column,
ranged from 5% to 90%. The majority of what was recov-
ered from the columns (>90%) was found in the FFA frac-
tion, suggesting similar polarity of epoxy, hydroxy, and
ketone oxylipins to FFA. However, there were a few excep-
tions. These were LNA-derived 9(10)-EpOME and AA-
derived 15-oxo-eicosatetraenoic acid (oxo-ETE) separated
with the 100 mg column, and LNA-derived 12(13)-
EpOME separated with both columns. 9(10)-EpOME and
12(13)-EpOME showed some recovery in NL (16–24%).
More 15-oxo-ETE was retained in NL (7%) than in
FFA (5%).
Total recovery of prostaglandins, leukotrienes (LT),
thromboxanes, dihydroxy, and trihydroxy metabolites was
low, and the separation was inefﬁcient, meaning that many
did not end up in the FFA fraction. Their recovery ranged
between 24% and 76% on the 100 mg column and between
20% and 84% on the 500 mg column. Dihydroxy metabo-
lites eluted in FFA and PL, whereas prostaglandins, LT,
thromboxanes, and trihydroxy metabolites eluted almost
exclusively with PL.
Analysis of Brain Samples with the 100 and 500 mg
Aminopropyl Columns
Total lipids extracted from one brain hemisphere of a CO2-
asphyxiated rat were separated with each of the 100 and
500 mg aminopropyl columns in order to explore the vari-
ance associated with separating oxylipins esteriﬁed to NL
and PL with each column (n = 3/column). NL and PL were
collected, hydrolyzed after adding deuterated surrogate
standards, and quantiﬁed by UPLC–MS/MS. The means,
SD, and coefﬁcients of variation for each column are pres-
ented in Table 4. As shown, the coefﬁcients of variation for
oxylipins bound to NL and PL were much lower with the
500 mg aminopropyl columns compared to the 100 mg col-
umns. More oxylipins were detected in NL when using the
500 mg column compared to the 100 mg column, likely
because more total lipids were loaded onto the 500 mg col-
umn (~1 mg) than the 100 mg column (~0.2 mg), resulting
in an enhanced signal on the UPLC–MS/MS.
For detected compounds, concentrations of esteriﬁed
ARA- and DHA-derived epoxides within NL and PL did
Table 2 Percent recovery of unesteriﬁed and esteriﬁed palmitate within FFA, NL, and PL separated with 100 or 500 mg aminopropyl columns
(n = 1 per standard per column)
100 mg column 500 mg column
NL (%) FFA (%) PL (%) NL (%) FFA (%) PL (%)
Palmitic acid (FFA) 3 93 3 8 92 1
Cholesteryl-palmitate (CE) 82 5 6 105 3 3
Tripalmitin (TAG) 109 2 2 101 1 1
DPPC (PL) 22 3 102 4 1 92
Abbreviations: CE, cholesteryl esters; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; FFA, unesteriﬁed fatty acids; TAG, triacylglycerols;
NL, neutral lipids; PL, phospholipids. n = 1 for CE, DPPC, FFA, and TAG standards applied to each of the two columns.
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not statistically differ between the 100 and 500 mg col-
umns. The only detected EPA-derived metabolite, 14(15)-
EpETE, was 10 times lower in PL separated with the
500 mg column compared to the 100 mg col-
umn (p < 0.05).
Concentrations of several LNA-derived metabolites (9
(10)- and 12(13)-EpOME, 9,10- and 12,13-DiHOME, 9-
and 13-HODE, 9-oxo-octadecadienoic acid [oxo-ODE]),
ARA-derived hydroxylated metabolites (HETE), and EPA-
derived hydroxylated compounds (15-HEPE) were signiﬁ-
cantly lower in NL and PL by 23–96% with the 500 mg
column compared to the 100 mg column. It is not clear
why these differences were found between the 100 and
500 mg columns. The lack of esteriﬁed analytical standards
makes it difﬁcult to know whether the concentration differ-
ences were due to losses during the column separation or
ion suppression.
Overall, our data indicate that the 500 mg column reli-
ably separates esteriﬁed epoxides of ARA and DHA
because (1) many unesteriﬁed long-chain PUFA epoxides
did not coelute with esteriﬁed NL and PL when using the
500 mg column compared to the 100 mg column (Table 3),
and (2) although rat brain ARA and DHA epoxide concen-
trations were statistically similar between the two
columns, the coefﬁcient of variation was lower with the
500 mg column, suggesting better reproducibility
(Table 4). Thus, the 500 mg column was used to test the
effects of hypercapnia/ischemia on brain-esteriﬁed ARA
and DHA epoxide concentrations (following section).
Hypercapnia-Ischemia Study
Data showing the percent of ARA-, EPA-, and DHA-
derived epoxides detected in brain PL and NL of each of
the MW-irradiated and CO2-asphyxiated groups are shown
in Supplementary Table 5. As shown, most of the fre-
quently detected compounds were ARA- and DHA-derived
epoxides.
Means and SD, as well as medians and interquartile
ranges, of ARA and DHA epoxides within PL and NL are
presented in Supplementary Table 6. Published values for
corresponding free oxylipins from the same rats are also
presented in Supplementary Table 6 (Hennebelle
et al., 2019).
The data for PL-bound epoxides of ARA and DHA were
highly variable and not normally distributed
(Supplementary Table 6). Statistical analysis by Mann–
Whitney U test showed no signiﬁcant differences in PL-
bound epoxides between the MW-irradiated and CO2-
asphyxiated groups (p > 0.05).
NL-bound ARA epoxides were normally distributed and
therefore analyzed by unpaired t-test; NL-bound DHA
epoxides failed the normality of distribution test (in theTa
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Table 4 Brain oxylipin concentrations (pmol/g) in NL and PL separated post-Folch extraction with the 100 and 500 mg aminopropyl columns.
The brain was from one rat euthanized by CO2-induced hypercapnia/ischemia
100 mg column 500 mg column
NL fraction PL fraction NL fraction PL fraction
Concentration CV
(%)
Concentration CV
(%)
Concentration CV
(%)
Concentration CV
(%)
Epoxy- 9(10)-EpOME 1262.6  113.9 9 951.0  159.7 17 533.4  83.0* 16 504.1  27.1* 5
12(13)-EpOME 3001.5  194.4 6 1511.1  320.7 21 1158.9  134.5* 12 350.5  16.5* 5
5(6)-EpETrE ND — 1378.7  615.9 45 ND — 1477.3  287.5 19
8(9)-EpETrE ND — 1591.9  616.6 39 12.8  2.9 23 822.1  74.5 9
11(12)-EpETrE ND — 1336.2  483.2 36 14.2, 15.6 1276.9  191.1 15
14(15)-EpETrE ND — 4728.4  2570.5 54 20.0, 22.0 3899.0  341.8 9
8(9)-EpETE ND — 235.8 — ND — ND —
11(12)-EpETE ND — 72.0 — ND — 16.0 —
14(15)-EpETE ND — 137.6  76.5 56 ND — 13.8  3.1* 22
17(18)-EpETE ND — 1826.6 — ND — 125.3 —
7(8)-EpDPE ND — 2719.2  1089.0 40 ND — 1903.2  262.6 14
10(11)-EpDPE 14.9 — 2947.9  1176.0 40 12.8  2.9 22 2068.7  190.0 9
13(14)-EpDPE ND — 3612.9  1543.6 43 28.5, 10.3 2773.3  282.9 10
16(17)-EpDPE ND — 3722.1  1779.8 48 ND — 3051.2  325.0 11
19(20)-EpDPE ND — 5971.6  2522.9 42 ND — 2646.0  78.5 3
Dihydroxy- 9,10-DiHOME 45.0  3.4 7 161.9  22.1 14 18.5  3.0* 16 66.4  6.1* 9
12,13-DiHOME 60.3, 29.3 245.6  28.3 12 26.5  3.5 13 124.6  18.3* 15
5,6-DiHETrE ND — 439.0  183.7 42 ND — 503.9  56.0 11
8,9-DiHETrE ND — 55.4 — ND — 38.0, 30.4
11,12-DiHETrE ND — ND — ND — 23.6  11.4 48
14,15-DiHETrE ND — 36.5  11.0 30 ND — 43.0  16.8 39
8,15-DiHETE ND — ND — ND — 169.0  18.3 11
Hydroxy- 9-HODE 1348.2  307.4 23 1434.9  321.5 22 165.4  43.6* 26 162.3  45.6* 28
13-HODE 1563.0  461.6 30 1772.0  468.0 26 284.3  158.4* 56 240.5  128.7* 54
15(S)-HETrE ND — ND — ND — 8.0, 8.5
5-HETE ND — 261.3  28.0 11 ND — 145.3  8.0* 5
8-HETE ND — 108.1  21.2 20 ND — 61.3  0.1* 0
11-HETE ND — 151.0  35.6 24 ND — 70.2  5.1* 7
12-HETE ND — 95.5  13.3 14 ND — 73.5  21.2 29
15-HETE ND — 253.7  82.4 32 ND — 166.2  33.7 20
20-HETE ND — 1151.9, 836.6 ND — 125.4, 109.3
5-HEPE 640.9, 103.2 866.6  573.8 66 ND — 34.2  13.2 38
8-HEPE 137.2 — 627.4  399.7 64 ND — 23.6  4.3 18
12-HEPE 1206.3, 894.1 6859.7  5002.9 73 221.8, 58.6 1170.6  351.2 30
15-HEPE 317.4 — 1883.9  709.6 38 ND — 601.8  121.5* 20
Ketones,
LTB
9-oxo-ODE 364.8  121.2 33 448.7  95.1 21 74.8  29.8* 40 38.3  15.5* 41
13-oxo-ODE ND — 614.0 — ND — 62.1 —
15-oxo-ETE ND — 27.1, 43.8 ND — 16.2, 21.2
20-COOH-
LTB4
387.0  57.3 15 314.1, 253.7 69.0  6.6* 10 n.d. —
Data are mean  SD (n = 3/column). Raw values are presented for oxylipins detected in one or two of three samples.
Abbreviations: ND, not detected; NL, neutral lipids; PL, phospholipids; EpOME, epoxyoctadecenoic acid; EpETrE, epoxyeicosatrienoic acid;
EpETE, epoxyeicosatetraenoic acid; EpDPE, epoxydocosapentaenoic acid; DiHOME, dihydroxyoctadecenoic acid; DiHETrE,
dihydroxyeicosatrienoic acid; DiHETE, dihydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; HETrE, hydroxyeicosatrienoic
acid; HETE, hydroxyeicosatetraenoic acid; HOTrE, hydroxyoctadecatrienoic acid; HEPE, hydroxyeicosapentaenoic acid; HDoHE, hydro-
xydocosahexaenoic acid; LT, leukotriene.
*p < 0.05 between 100 and 500 mg columns per lipid fraction by unpaired t-test.
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CO2 group only), so a Mann–Whitney U test was used.
Fig. 1a shows mean (SD) PUFA epoxide concentrations
in brain NL of rats subjected to high-energy microwave ﬁx-
ation (controls) and CO2-induced hypercapnia/ischemia
(mean and median values also provided in Supplementary
Table 6). As shown, brain concentrations of ARA-derived
11(12)- and 14(15)-EpETrE were signiﬁcantly increased in
the CO2 group, compared to MW controls, by 60% and
112%, respectively (Fig. 1a; p < 0.05 by unpaired t-test).
DHA-derived 7(8)-EpDPE, 10(11)-EpDPE, and 16(17)-
EpDPE were signiﬁcantly decreased by 32%, 37%, and
27%, respectively, in the CO2 group compared to MW con-
trols (p < 0.05 by Mann–Whitney U test; Fig. 1a).
Published mean values of unesteriﬁed ARA and DHA
epoxide concentrations measured in the second hemisphere
of the same rats are shown in Fig. 1b (Hennebelle et al.,
2019). For these measurements, the brains were extracted
with methanol, puriﬁed with Oasis HLB columns, and
analyzed with UPLC–MS/MS as reported (Hennebelle
et al., 2019). 8(9)-EpETrE was analyzed by an unpaired t-
test because it was normally distributed, whereas other
metabolites were analyzed by Mann–Whitney U because
they were not normally distributed in one or two groups.
As shown in Fig. 1b, unesteriﬁed ARA- and DHA-derived
epoxides were signiﬁcantly higher by 7–57-fold following
CO2-induced hypercapnia/ischemia relative to microwave
ﬁxation. Unesteriﬁed 7(8)-EpDPE, while present in PL and
NL, was not detected in the free oxylipin pool.
Pathway Depiction
Fig. 2 depicts plausible pathways that regulate the turnover
of fatty acid epoxides within rat brain lipids. As shown,
PUFA-derived epoxides can be liberated from membrane
PL or NL via lipase enzymes and re-esteriﬁed via acyl-
CoA synthetase and acyltransferase enzymes. Speciﬁc
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Fig. 1 Concentration of arachidonic acid (ARA)- and docosahexaenoic acid (DHA)-derived epoxides in (a) neutral lipids (NL) and
(b) unesteriﬁed fatty acids (FFA) (adapted from Hennebelle et al. (2019)) of rats subjected to head-focused microwave ﬁxation (MW) or CO2-
induced hypercapnia/ischemia (CO2). Data are mean  SD (n = 8 per group). *p < 0.05; **p < 0.01; ***p < 0.001 (Unpaired t-test or Mann–
Whitney U test). Abbreviations: EpETrE, epoxyeicosatrienoic acid; EpDPE, epoxydocosapentaenoic acid; ND, not detected
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enzyme isoforms that regulate this pathway remain to be
determined, although Acyl-CoA synthetase 4 was shown to
incorporate EpETrE into PL (Klett et al., 2017).
Discussion
In the present study, we validated an aminopropyl column
method for separating PL- and NL-bound epoxides of long-
chain PUFA and demonstrated that hypercapnia/ischemia
altered ARA and DHA epoxides within NL. Speciﬁcally,
the concentrations of two ARA-derived epoxides (11(12)-
and 14(15)-EpETrE) were increased by 60–112%, and three
DHA-derived epoxides (7(8)-EpDPE, 10(11)-EpDPE and
16(17)-EpDPE) were decreased by 27–37% in brain NL of
rats subjected to CO2-induced hypercapnia/ischemia com-
pared to MW-irradiated controls. This suggests the pres-
ence of a turnover pathway that regulates ARA and DHA
epoxide levels within NL (Fig. 2).
With regard to the aminopropyl separation method, FFA,
PL, and NL standards separated well with the 500 mg col-
umn (Table 2). Unesteriﬁed PUFA-derived hydroxy,
epoxy, and ketone oxylipin standards applied to both col-
umns eluted with the FFA pool as expected despite the low
recovery for some alcohol and ketone compounds
(Table 3), possibly due to degradation or elution during one
of the wash steps listed in Table 1. The elution of
unesteriﬁed hydroxy, epoxy, and ketone oxylipins with the
FFA pool indicates that, if present in the sample, they are
not likely to coelute with PL or NL.
Both 100 and 500 mg columns had some fatty acid con-
taminants in them despite being washed with organic
solvents and acid. LNA and ALA (but not other PUFA)
contaminants present in NL, PL, and FFA and separated by
the 100 and 500 mg columns (Supplementary Table 4)
might produce LNA- and ALA-derived oxylipin artifacts.
This is why we chose to focus on ARA-, EPA-, and DHA-
derived oxylipins, as metabolites of LNA and ALA cannot
be reliably quantiﬁed after column separation.
The separation of brain total lipids using both 100 and
500 mg columns yielded comparable results for ARA- and
DHA-derived epoxides, although the variance was lower,
and the number of detected compounds was higher when
the extracted lipids were separated using the 500 mg col-
umn relative to the 100 mg column (Table 4). EPA-derived
epoxides were rarely detected with either column. Differ-
ences in column recovery for other compounds
(e.g. hydroxy and ketone PUFA metabolites) are difﬁcult to
explain in the absence of authentic esteriﬁed oxylipin stan-
dards. Thus, only ARA- and DHA-derived epoxides bound
to NL and PL were considered reliable to quantify using
the 500 mg column.
The 60–112% increase in ARA-derived epoxides in brain
NL of rats subjected to CO2-induced hypercapnia/ischemia
relative to microwave-irradiated controls (Fig. 1a) could be
due to increased free ARA-epoxide esteriﬁcation, decreased
lipase-mediated release of epoxy ARA bound to NL, or
direct epoxidation of ARA esteriﬁed to NL. Increased free
ARA-epoxide esteriﬁcation is a likely mechanism
explaining the increase in ARA-epoxide in NL because of
the observed increase in free ARA-epoxide concentrations
following CO2-induced hypercapnia/ischemia (Fig. 1b).
Free ARA epoxides are substrates for acylation and esteriﬁ-
cation by acyl CoA synthetase and acyltransferase, respec-
tively (Klett et al., 2017). A reduction in lipase-mediated
release is unlikely because the concentration of unesteriﬁed
epoxy-ARA metabolites was increased in the CO2-
asphyxiated group compared to microwave controls
(Fig. 1b). Notably, the hydroxylation of PL was reported to
occur in vitro (Chaitidis et al., 1998) and in peripheral
immune cells via LOX (Slatter et al., 2018; Uderhardt
et al., 2017), but to our knowledge, direct epoxidation of
esteriﬁed PUFA (to NL) has not been demonstrated. Future
studies should resolve the mechanisms of esteriﬁed epoxide
ARA formation in NL in vivo.
DHA-derived 7(8)-EpDPE was lower in brain NL of
CO2-asphyxiated rats compared to MW controls.
Unesteriﬁed 7(8)-EpDPE was not detected (Hennebelle
et al., 2019). It is possible that 7(8)-EpDPE is selectively
retained in PL and NL. The decrease in its concentration
within NL following ischemia/hypercapnia could be due to
(1) its conversion into diols within NL via epoxide hydrolase
or (2) rapid lipase-mediated release and degradation via
sEH. These hypotheses should be tested once better assays
for esteriﬁed diols within PL and NL become available.
Epoxy-PL / Epoxy-TAG/ Epoxy-CE
Lipase Acyl-CoA Synthetase / Acyltransferase
Epoxy-ARA/DHA (free)
+ 
LysoPL / DAG/ Cholesterol
Fig. 2 Pathways regulating the turnover of fatty acid epoxides within
rat brain lipids. As shown, polyunsaturated fatty acids (PUFA)-
derived epoxides can be liberated from membrane phospholipids
(PL) or neutral lipids (NL) via lipase enzymes and re-esteriﬁed via
acyl-CoA synthetase and acyltransferase enzymes. The acylation of
free epoxy-ARA or epoxy-DHA (via acyl synthetases) enables their
esteriﬁcation to lysophospholipids (LysoPL), diacylglycerols (DAG)
or cholesterol via acyltransferase enzymes. This generates epoxy-PL/
TAG/CE (i.e. a PL, TAG or CE containing epoxidized ARA or
DHA). LysoPL can also be directly oxidized by LOX, and then esteri-
ﬁed to a saturated fatty acid as recently described by Liu et al., 2019.
The observed increase in arachidonic acid (ARA)-derived epoxides
and reduction in docosahexaenoic acid (DHA)-derived epoxides dur-
ing hypercapnia/ischemia could be explained by changes in acyl
synthethase/acyltranferase-mediated esteriﬁcation and/or lipase-
mediated release
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DHA-derived 10(11)-EpDPE and 16(17)-EpDPE were
also lower in NL of CO2-asphyxiated rats compared to
MW controls but were higher in the free pool. The decrease
in NL-bound DHA epoxides (and concomitant increase in
unesteriﬁed concentrations) could be due to increased
lipase-mediated hydrolysis from NL-bound epoxides dur-
ing hypercapnia/ischemia. However, given the magnitude
of changes in free versus NL-bound 10(11)-EpDPE and
16(17)-EpDPE (Fig. 1), CYP-mediated synthesis of
unesteriﬁed DHA epoxides (from free DHA) likely
explains the increase in their concentration during hyper-
capnia/ischemia.
Previously, we reported that up to approximately 90% of
oxylipins in the brain are esteriﬁed to complex lipids, but
the lipid species to which they are bound have not been
characterized (Taha et al., 2018). In the present study, we
demonstrated that the majority of oxylipins were esteriﬁed
to PL (Table 3; Supplementary Table 6). Quantitatively,
PL-bound ARA and DHA epoxides, although variable,
were approximately 39–214 more abundant (across the
two groups) than NL-bound epoxides. NL PUFA epoxides
were similar in concentration to unesteriﬁed oxylipins
(Fig. 1). These observations reﬂect in vivo regulatory path-
ways that control oxylipin turnover (esteriﬁcation and
release) within brain lipid pools, particularly during hyper-
capnia/ischemia, as proposed in Fig. 2. This turnover path-
way could regulate free oxylipin availability alongside
other established pathways involving lipase-mediated
release of PUFA from esteriﬁed lipid pools and their oxi-
dation via CYP, LOX, COX, or other enzymes to form free
oxylipins.
The variability in brain-oxidized PL was high
(Supplementary Table 6). It is unlikely that this was due to
the SPE fractionation process because none of the
unesteriﬁed epoxides of interest eluted with PL (Table 3),
and the authentic standard (1,2-dipalmitoyl-sn-glycero-
3-phosphocholine) separated well with the 500 mg column
used in the rodent study (Table 2). Oxidized PL, however,
are slightly more polar than nonoxidized PL. Hence, one
explanation of the variability could be partial loss of oxidized
PL within the aqueous phase of the Folch extract. Another
explanation is that a small but non-trivial amount of free
oxylipins coeluted with oxidized PL due to their similar
polarities. In the absence of oxidized PL authentic standards,
these scenarios cannot be veriﬁed. Notably, the variability in
oxidized PL was low when the same sample was analyzed
thrice (technical replicates; Table 3). This points to the possi-
bility that the variability could be biological, arising from the
rapid remodeling of epoxide PL. The half-lives and remo-
deling rates of epoxidized PL in the brain are not known.
CO2 asphyxiation is a common euthanasia technique.
Thus, the observed changes in NL-bound epoxides follow-
ing CO2 asphyxiation have implications on other studies
using this technique as a euthanasia method. Compared to
MW-irradiated controls, the magnitude of changes follow-
ing CO2 asphyxiation was smaller in NL (27–112%, Fig. 1)
than in free oxylipins, where increases of up to 155-fold
were observed (Hennebelle et al., 2019). This indicates that
postmortem ischemia minimally impacts the esteriﬁed
PUFA-epoxide pool compared to the unesteriﬁed pool,
suggesting that it can be used as a more reliable marker of
disturbed brain oxylipin metabolism.
A limitation of this study is that regional changes in
esteriﬁed oxylipins were not explored, because measure-
ments were taken from whole brain. It would be worth-
while to examine ischemia-induced changes in esteriﬁed
oxylipins across brain regions and cell types (glia vs neu-
rons) to better understand vulnerable brain areas or cell
populations. In addition, the contribution of esteriﬁed
oxylipins originating from peripheral blood vessels is not
known. Hypercapnia/ischemia is known to increase blood
ﬂow to the brain, which means that the changes seen in
esteriﬁed oxylipins could originate, in part, from peripheral
blood. Finally, it should be noted that base hydrolysis of
esteriﬁed oxylipins at 60 C could potentially generate oxi-
dation artifacts. Determining the contribution of such arti-
facts to the biological signal using authentic esteriﬁed
standards (when they become commercially available)
would be paramount to conﬁrming our results.
In summary, this study provides new in vivo evidence
that acute brain injury induced by hypercapnia/ischemia
increases ARA epoxides and decreases DHA epoxides
esteriﬁed to NL, in parallel to the recently described
increases in unesteriﬁed ARA and DHA epoxides
(Hennebelle et al., 2019). These ﬁndings suggest an active
turnover pathway involved in transporting unesteriﬁed
ARA- and DHA-derived epoxides within esteriﬁed lipid
compartments in rat brain. The enzymatic machinery regu-
lating this process remains to be characterized. As ARA-
and DHA-derived epoxides are important mediators of
cerebral vascular tone with anti-inﬂammatory and
proresolving properties (reviewed by Swardfager et al.,
2018), identifying and targeting the enzymes involved in
their turnover within NL provides new potential for treating
ischemic or other types of brain injury.
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Supplementary Table 1.  UPLC-MS/MS analytical parameters 
Compound Fatty acid precursor 
Precursor 
Ion 
Product  
Ion 
Fragmentat
ion voltage 
(V) 
Collision 
Energy (V) 
Retention Time 
(min) 
Ep
ox
y-
 
9(10)-EpOME LNA 295.3 171.1 100 7 22.07 
12(13)EpOME LNA 295.3 195.2 95 7 21.65 
5(6)-EpETrE ARA 319.2 191.1 115 4 23.75 
8(9)-EpETrE ARA 319.2 167.2 90 4 23.12 
11(12)-EpETrE ARA 319.2 167.2 105 4 23.4 
14(15)-EpETrE ARA 319.2 219.3 130 4 22.1 
8(9)-EpETE EPA 317.2 127.2 115 4 19.95 
11(12)-EpETE EPA 317.2 167.2 90 4 19.67 
14(15)-EpETE EPA 317.2 207.2 100 4 19.42 
17(18)-EpETE EPA 317.2 215.2 130 4 18.4 
7(8)-EpDPE DHA 343.2 113.1 85 4 23.35 
10(11)-EpDPE DHA 343.2 153.2 90 4 22.97 
13(14)-EpDPE DHA 343.2 193.2 80 4 22.8 
16(17)-EpDPE DHA 343.2 233.2 130 4 22.62 
19(20)-EpDPE DHA 343.2 241.2 130 7 21.7 
Di
hy
dr
ox
y-
 
9,10-DiHOME LNA 313.2 201.2 130 16 12.42 
12,13-DiHOME LNA 313.2 183.2 130 16 11.95 
5,6-DiHETrE ARA 337.2 145.1 85 7 15.82 
8,9-DiHETrE ARA 337.2 127.1 85 13 14.75 
11,12-DiHETrE ARA 337.2 167.1 120 13 14.02 
14,15-DiHETrE ARA 337.2 207.1 130 10 13.15 
5,15-DiHETE ARA 335.2 173.2 95 7 10.83 
8,15-DiHETE ARA 335.2 235.2 90 7 10.4 
5,6-DiHETE EPA 335.2 115.2 90 4 10.85 
14,15-DiHETE EPA 335.3 207.2 95 7 11.57 
17,18-DiHETE EPA 335.3 247.2 105 7 11 
Hy
dr
ox
y-
 
9-HODE LNA 295.2 171.1 120 10 17.42 
13-HODE LNA 295.2 195.2 95 13 17.25 
15(S)-HETrE DGLA 321.2 221.2 85 7 20.15 
5-HETE ARA 319.2 115.1 90 10 20.55 
8-HETE ARA 319.2 155.2 120 7 19.55 
9-HETE ARA 319.2 167.2 80 7 20.05 
11-HETE ARA 319.2 167.2 100 7 18.94 
12-HETE ARA 319.2 179.2 120 7 19.6 
15-HETE ARA 319.2 219.2 120 4 18.23 
20-HETE ARA 319.2 275.1 125 10 15.7 
9-HOTrE ALA 293.2 171.2 110 4 14.42 
13-HOTrE ALA 293.2 195.1 125 10 14.83 
5-HEPE EPA 317.2 115.1 115 4 17.05 
8-HEPE EPA 317.2 155.2 115 7 16.17 
12-HEPE EPA 317.2 179.2 110 4 16.42 
15-HEPE EPA 317.2 219.2 90 4 15.8 
17-HDoHE DHA 343.2 281.2 95 4 18.62 
Ke
to
- 
9-oxo-ODE LNA 293.2 185.1 90 13 19.25 
13-oxo-ODE LNA 293.2 195.1 95 13 18.44 
5-oxo-ETE ARA 317.2 273.2 120 7 22.83 
12-oxo-ETE ARA 317.2 153.1 115 7 20.45 
15-oxo-ETE ARA 317.2 113.1 125 10 19.3 
Le
uk
ot
rie
ne
s, 
pr
os
ta
gl
an
nd
in
s, 
tr
om
bo
xa
ne
s, 
Re
so
lv
in
 a
nd
 tr
ih
yd
ro
- 
LTB3 ETA 337.2 195.2 120 7 13.38 
20-COOH-LTB4 ARA 365.2 347.2 120 7 3.7 
20-OH-LTB4 ARA 351.2 195.2 95 13 4.32 
6-trans-LTB4 ARA 335.2 195.1 125 7 10.8 
LTB4 ARA 335.2 195.1 125 7 11.27 
LTC4 ARA 624.3 272.1 70 22 8.9 
LTD4 ARA 495.3 177.1 55 13 7.3 
LTE4 ARA 438.2 333.3 90 13 8.9 
LXA4 ARA 351.2 115.2 95 10 7.55 
PGB2 ARA 333.3 175.1 125 13 9.45 
PGD1 DGLA 353.3 317.2 75 7 6.9 
PGD2 ARA 351.2 271.3 80 10 6.9 
PGD3 EPA 349.3 269.2 120 7 5.9 
PGE1 DGLA 353.3 317.2 75 7 6.72 
PGE2 ARA 351.2 271.3 80 10 6.5 
PGE3 EPA 349.3 269.2 120 7 5.6 
6-keto-PGF1α ARA 369.3 163.2 90 22 4 
PGF2α ARA 353.2 309.2 120 10 6.25 
PGJ2 ARA 333.3 189.2 90 10 9.32 
15-deoxy-PGJ2 ARA 315.2 271.2 130 4 15.35 
Resolvin E1 EPA 349.3 195 115 10 4.05 
TXB2 ARA 369.2 169.1 80 10 6 
9,10,13-TriHOME LNA 329.2 171.1 110 16 6.2 
9,12,13-TriHOME LNA 329.2 211.1 125 16 6.1 
Su
rr
og
at
e 
d-11-11(12)EpEtrE  330.2 167.2 80 7 22.93 
d11-14,15-DiHETrE  348.2 207.1 125 10 13.02 
d4-6-keto-PGF1a  373.3 167.1 90 19 4 
d4-9-HODE  299.2 172.3 90 13 17.25 
d4-LTB4  339.2 197.2 80 10 11.22 
d4-PGE2  355.2 275.3 90 7 6.5 
d4-TXB2  373.3 173.2 105 10 6 
d6-20-HETE  325.2 281.2 110 7 15.62 
d8-5-HETE  327.2 116.1 75 7 20.3 
Abbreviations: ARA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; 
ETA; eicosatrienoic acid; LNA, linoleic acid, DGLA, dihomo-gamma-linolenic acid; ALA, alpha-
linolenic acid; HODE, hydroxyoctadecadienoic acid; oxo-ODE, oxo-octadecadienoic acid; 
EpOME, epoxyoctadeenoic acid; DiHOME, dihydroxyoctadecenoic acid; TriHOME, 
trihydroxyoctadecenoic acid; EpETrE, epoxyeicosatrienoic acid; DiHETrE, 
dihydroxyeicosatrienoic acid; HETE, hydroxyeicosatetraenoic acid; oxo-ETE, oxo-
eicosatetraenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; LT, leukotriene; PG, 
prostaglandin; TXB2, tromboxane B2; HOTrE, hydroxyoctadecatrienoic acid; EpETE, 
epoxyeicosatetraenoic acid; HEPE, hydroxyeicosapentaenoic acid; EpDPE, 
epoxydocosapentaenoic acid; HDoHE, hydroxydocosahexaenoic acid; HETrE, 
hydroxyeicosatrienoic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2:  UPLC gradient condition  
time (min) B conc (%) flow (ml/min) 
0 35 0.3 
3 40 0.25 
4 48  
10 60  
20 75  
22 85  
23 85 0.25 
23.1 99 0.35 
25.5 99  
25.6 35 0.35 
27 35 0.3 
27.5 Stop 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3: Purity of unesterified and esterified palmitic acid standards applied to 
the aminopropyl columns 
 Unesterified and esterified palmitic acid standards 
 Unesterified 
16:0 
Cholesteryl 
palmitate DPPC Tripalmitin 
Palmitic acid (C16:0) 99.5% 98% 98.7% 99.1% 
Palmitoleic acid 
(C16:1 n-7) 
0.3% 1.2% 0.8% 0.5% 
Unknown peak at 10.5 
min 
0.2% 0.8% 0.5% 0.4% 
DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine. n=1 per standard applied to the columns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 4: Amount of fatty acids (in µmol) detected in FFA, NL and PL separated 
using the 100 mg and 500 mg aminopropyl columns.  
 100 mg column 500 mg column 
FFA        
Unknown peak at 10.5 min  13.1 ± 1.7 13.2 ± 1.3 
Palmitoleic acid (16:1 n-7) 17.6 ± 2.3 17.5 ± 0.8 
Stearic acid (18:0) 4.8 ± 3.7 25.7 ± 12.4* 
Oleic acid (18:1 n-9) 10.1 ± 7.6 48.9 ± 23.9* 
Linoleic acid (18:2 n-6) 20.3 ± 15.9 101.7 ± 51.6* 
α-linolenic acid (18:3 n-3) n.d. 11.7 ± 5.9* 
Total fatty acids1 65.9 ± 26.3 222.5 ± 100.1* 
NL        
Unknown peak at 10.5 min 14.5 ± 2.0 13.6 ± 0.9 
Palmitoleic acid (16:1 n-7) 19.0 ± 2.6 18.5 ± 1.0 
Stearic acid (18:0) 24.6 ± 18.1 90.0 ± 38.4* 
Oleic acid (18:1 n-9) 125.9 ± 97.4 471.2 ± 205.0* 
Linoleic acid (18:2 n-6) 286.3 ± 220.9 1078.0 ± 465.3* 
α-linolenic acid (18:3 n-3) 35.5 ± 26.2 130.5 ± 55.5* 
Total fatty acids1 512.5 ± 374.1 1850.9 ± 792.2* 
PL        
Unknown peak at 10.5 min 14.6 ± 0.9 13.7 ± 3.0 
Palmitoleic acid (16:1 n-7) 18.7 ± 1.9 16.2 ± 3.4 
Stearic acid (18:0) 22.3 ± 1.8 34.3 ± 2.4* 
Oleic acid (18:1 n-9) n.d. 3.9 ± 7.9 
Linoleic acid (18:2 n-6) n.d. 5.3 ± 10.7 
α-linolenic acid (18:3 n-3) n.d. n.d. 
Total fatty acids1 55.7 ± 2.9 77.6 ± 30.3* 
Data are mean ± SD (n=4) of fatty acids quantified in each fraction (FFA, NL and PL) following 
the addition of   free palmitate, cholesteryl palmitate, tripalmitin and DPPC to each column (n=1 
per standard per column type). 
* indicates statistically significant differences between 100 mg and 500 mg column by unpaired t-
test, p<0.05. 
1Totals include the unknown peak at 10.5 min.  
Abbreviations: FFA, unesterified fatty acids; NL, neutral lipids; PL, phospholipids; n.d., not 
detected. 
The unidentified compound corresponding to the 10.5 min peak and palmitoleic acid present in 
the standards prior to separation were detected in all fractions. Other fatty acids detected in the 
FFA, NL and PL were stearic acid (18:0), oleic acid (18:1 n-9), linoleic acid (18:2 n-6) and α-
linolenic acid (18:3 n-3).  The concentration of these fatty acids within each of these fractions was 
significantly higher with the 500 mg column compared to the 100 mg (P<0.05 by unpaired t-test). 
Regardless of column size, NL contained the highest amount of fatty acid contaminants (55 to 59% 
of all fatty acid detected), followed by FFA and PL.  Total fatty acid contaminants of all three 
fractions (including the unidentified peak and palmitoleic acid) equaled 634 ± 400.8 µmol and 
2151 ± 860.3 µmol in the 100 mg and 500 mg columns, respectively. 
 
Supplementary Table 5. Percentage of quantifiable EPA, DHA and ARA derived epoxides in 
brain PL and NL of rats subjected to head-focused microwave irradiation (MW-group) or CO2 
asphyxiation (CO2-group). Oxylipins were quantified if they were detected above the limits of 
quantitation, defined as a signal to noise ratio greater than 10.   
 
 PL NL 
 MW-group CO2-group MW-group CO2-group 
5(6)-EpETrE 75% 88% 38% 88% 
8(9)-EpETrE 75% 88% 75% 88% 
11(12)-EpETrE 75% 88% 100% 100% 
14(15)-EpETrE 75% 88% 100% 100% 
8(9)-EpETE 0% 0% 0% 0% 
11(12)-EpETE 50% 25% 38% 38% 
14(15)-EpETE 13% 0% 0% 0% 
17(18)-EpETE 0% 0% 0% 0% 
7(8)-EpDPE 100% 100% 100% 100% 
10(11)-EpDPE 75% 88% 100% 100% 
13(14)-EpDPE 88% 88% 100% 100% 
16(17)-EpDPE 75% 88% 100% 100% 
19(20)-EpDPE 100% 88% 88% 100% 
Abbreviations: PL, phospholipids; NL, neutral lipids; EpETrE, epoxyeicosatrienoic acid; EpETE, 
epoxyeicosatetraenoic acid; EpDPE, epoxydocosapentaenoic acid.
Supplementary Table 6. ARA and DHA epoxide concentrations (pmol/g) in brain PL, NL and 
FFA of rats subjected to head-focused microwave fixation (MW group) or CO2 asphyxia for 2 
min (CO2 group). For each analyte, mean ± SD are presented in the first row, and median (25%, 
75% interquartile range) are presented in the second row. 
  MW group CO2 group  
PL 
 5(6)-EpETrE 1279.2 ± 2243.7 1090.1 ± 1776.9  
  15.6 (2.4 , 1906.4) 15.4 (7.8 , 2558.5)  
 8(9)-EpETrE 1296.7 ± 2334.3 1150.9 ± 1915.0  
  11.2 (3.6 , 2019.7) 13.9 (8.5 , 2657.9)  
 11(12)-EpETrE 1177.4 ± 2683.8 1036.2 ± 1872.6  
  12.7 (2.6, 845.7) 16.0 (6.9 , 1496.2)  
 14(15)-EpETrE 4166.5 ± 6541.3 2439.6 ± 3968.9  
  22.0 (2.5, 8613.7) 28.0 (18.4 , 4543.2)  
 7(8)-EpDPE 2150.9 ± 3764.7 1876.9 ± 3049.4  
  40.1 (36.1, 3232.9) 54.9 (31.9 , 4300.7)  
 10(11)-EpDPE  786.1 ± 1413.2 693.2 ± 1055.9  
  18.3 (3.9 , 1132.6) 28.5 (6.1 , 1319.2)  
 13(14)-EpDPE 1080.2 ± 1611.5 764.8 ± 1106.2  
  18.2 (4.4 , 2319.6) 24.4 (6.9 , 2054.7)  
 16(17)-EpDPE 1866.9 ± 2892.3 1282.3 ± 1905.2  
  21.1 (3.8 , 3800.1) 23.1 (5.1 , 3258.2)  
 19(20)-EpDPE 5351.6 ± 9111.5 3857.2 ± 6457.1  
  9058.4 (56.6 , 25796.3) 7057.1 (77.7 , 18087.1)  
NL 
 5(6)-EpETrE ND  11.7 ± 6.0  
   13.1 (6.8 , 16.3)  
 8(9)-EpETrE 9.3 ± 5.4 13.0 ± 7.8  
  10.3  (3.3 , 12.5) 13.4 (6.5 , 17.8)  
 11(12)-EpETrE 15.1 ± 3.9 24.2 ± 11.3*  
  14.9 (11.4 , 17.0) 20.3 (15.9, 36.3)  
 14(15)-EpETrE 19.5 ± 3.8 41.5 ± 21.2*  
  20.3 (16.4 , 22.5) 45.0 (19.3 , 60.5)  
 7(8)-EpDPE 49.3 ± 10.9 33.4 ± 10.4  
  49.2 (38.9 , 57.5) 31.2 (28.6 , 34.8)**  
 10(11)-EpDPE  20.4 ± 7.3 12.8 ± 7.8*  
  18.6 (15.4 , 26.0) 10.5 (8.5 , 12.0)  
    13(14)-EpDPE 19.5± 5.6 18.6 ± 10.7  
  19.2 (16.8 , 22.0) 15.8 (10.7 , 23.2)  
 16(17)-EpDPE 16.6 ± 5.9 12.2 ± 9.0  
  15.7 (11.8 , 19.9) 9.5 (7.0 , 13.0)*  
 19(20)-EpDPE 37.3 ± 17.2 33.5 ± 14.4  
  39.8 (30.8 , 50.9) 31.7 (24.2 , 32.5)  
FFA (extracted from ref [29]) 
 5(6)-EpETrE ND ND  
  ND ND  
 8(9)-EpETrE 0.02 ± 0.004 0.3 ± 0.1  
  0.02 (0.02, 0.02) 0.3 (0.2 , 0.5)***  
 11(12)-EpETrE 2.4 ± 1.3 94.1  ± 62.1  
  2.0 (1.5 , 2.9) 74.0 (50.8 , 157.4)***  
 14(15)-EpETrE 2.2 ± 0.9 127.8 ± 81.6  
  2.0 (1.6 , 2.7) 95.5 (68.8 , 215.2)***  
 7(8)-EpDPE ND ND  
  ND ND  
 10(11)-EpDPE  1.1 ± 0.9 7.7  ± 6.2  
  0.67 (0.4 , 1.8) 4.9 (3.9 , 11.6)***  
    13(14)-EpDPE 0.8 ± 0.7 7.4 ± 6.6  
  0.8 (0.2 , 0.9) 4.1 (3.6 , 13.3)***  
 16(17)-EpDPE 0.8 ± 0.6 9.8 ± 7.6  
  0.7 (0.3 , 1.0) 7.0 (4.4 , 17)***  
 19(20)-EpDPE 1.7 ± 0.9 17.0 ± 15.9  
  1.4 (1.2 , 2.4) 9.2 (8.0 , 24.9)***  
         
Data are expressed as mean ±SD and median (25th, 75th interquartile range). ND, not detected in 
at least 70% of samples (i.e. 30% or more values were below LOQ). For oxylipins with less than 
30% missing values (i.e. values below the LOQ), remaining missing values were set at LOD/root 
square of 2.  
Shapiro–Wilk’s test was used to test for normality. Data that failed the normality of distribution in 
at least one group were analyzed by Mann-Whitney U test. Normally distributed data were 
analyzed by an unpaired t-test. *p<0.05; **p<0.01 and p<0.001 by Mann-Whitney U or unpaired 
t-test.  
Abbreviations: PL, phospholipids; NL, neutral lipids; FFA, unesterified fatty acids; EpETrE, 
epoxyeicosatrienoic acid; EpDPE, epoxydocosapentaenoic acid. 
 
